Drug Profile
Research programme: integrin linked kinase inhibitors - Kinetek
Alternative Names: 307-2; ILK inhibitors research programme - Kinetek; Integrin linked kinase inhibitors research programme - Kinetek; KP 307-2; KP 392; Research programme: ILK inhibitors - KinetekLatest Information Update: 18 Aug 2006
Price :
$50
*
At a glance
- Originator Kinetek Pharmaceuticals
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Eye disorders; Inflammation; Kidney disorders
Most Recent Events
- 31 Dec 2005 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 31 Dec 2005 Discontinued - Preclinical for Eye disorders in Canada (unspecified route)
- 31 Dec 2005 Discontinued - Preclinical for Inflammation in Canada (unspecified route)